Logo image of CHMA

Chiasma Inc (CHMA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CHMA -

3.76
-0.24 (-6%)
Last: 8/5/2021, 8:18:03 PM
3.78
+0.02 (+0.53%)
After Hours: 8/5/2021, 8:18:03 PM
Fundamental Rating

2

Taking everything into account, CHMA scores 2 out of 10 in our fundamental rating. CHMA was compared to 192 industry peers in the Pharmaceuticals industry. While CHMA seems to be doing ok healthwise, there are quite some concerns on its profitability. CHMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CHMA had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -56.38%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -2408.65%
PM (TTM) -2968.35%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

CHMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -3.09, we must say that CHMA is in the distress zone and has some risk of bankruptcy.
CHMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.09
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

CHMA has a Current Ratio of 7.91. This indicates that CHMA is financially healthy and has no problem in meeting its short term obligations.
CHMA has a Quick Ratio of 7.08. This indicates that CHMA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 7.91
Quick Ratio 7.08

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CHMA have decreased strongly by -46.36% in the last year.
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CHMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.36% on average per year.
CHMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 280.08% yearly.
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%

3.3 Evolution

CHMA Yearly Revenue VS EstimatesCHMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
CHMA Yearly EPS VS EstimatesCHMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHMA. In the last year negative earnings were reported.
Also next year CHMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHMA Price Earnings VS Forward Price EarningsCHMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.42
CHMA Per share dataCHMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CHMA's earnings are expected to grow with 28.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.91%
EPS Next 3Y28.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CHMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Chiasma Inc

NASDAQ:CHMA (8/5/2021, 8:18:03 PM)

After market: 3.78 +0.02 (+0.53%)

3.76

-0.24 (-6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-03 2022-03-03/amc
Inst Owners0.88%
Inst Owner Change0%
Ins Owners2.83%
Ins Owner Change0%
Market Cap217.68M
Revenue(TTM)3.03M
Net Income(TTM)-89.94M
Analysts80
Price Target9.28 (146.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 71.84
P/FCF N/A
P/OCF N/A
P/B 3.47
P/tB N/A
EV/EBITDA -1.42
EPS(TTM)-1.61
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.05
BVpS1.08
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.38%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -2408.65%
PM (TTM) -2968.35%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.91
Quick Ratio 7.08
Altman-Z -3.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Chiasma Inc / CHMA FAQ

What is the ChartMill fundamental rating of Chiasma Inc (CHMA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CHMA.


What is the valuation status for CHMA stock?

ChartMill assigns a valuation rating of 1 / 10 to Chiasma Inc (CHMA). This can be considered as Overvalued.


Can you provide the profitability details for Chiasma Inc?

Chiasma Inc (CHMA) has a profitability rating of 1 / 10.


How financially healthy is Chiasma Inc?

The financial health rating of Chiasma Inc (CHMA) is 4 / 10.